Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 30, 2025
Intercept Announces Data to be Presented at Digestive Disease Week 2025
GlobeNewswire
·
April 30, 2025
MORRISTOWN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Intercept), part of the Alfasigma Group, today announced 11 submitted abstracts have been accepted for presentation at Digestive Disease Week 2025, including oral …
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
April 30, 2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus …
electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
GlobeNewswire
·
April 30, 2025
ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of …
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
GlobeNewswire
·
April 30, 2025
CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult …
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
GlobeNewswire
·
April 30, 2025
SYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of this quarter. That milestone will trigger an …
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
GlobeNewswire
·
April 30, 2025
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications and collaborations Plans to partially spin off RNA …
Best Testosterone Booster Supplement for Males Over 40: Why TestoPrime Leads for Muscle, Energy & Libido
GlobeNewswire
·
April 30, 2025
New York City, April 30, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Testosterone Support Matters After 40 As men age, maintaining strength, stamina, and masculinity becomes increasingly difficult — and one of the biggest reasons is a steady decline in …
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire
·
April 30, 2025
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
First AI-Driven Cognitive and Speech Therapy Platform for Spanish, English-Speaking Indian Communities
GlobeNewswire
·
April 30, 2025
LEXINGTON, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Constant Therapy Health, a pioneer in clinically proven digital AI-driven speech, language, and cognitive therapy, announces a significant expansion to its product offerings. The platform now includes …
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
GlobeNewswire
·
April 30, 2025
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology …
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
GlobeNewswire
·
April 30, 2025
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive …
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire
·
April 30, 2025
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …
Age, previous sports experience, stronger predictors of performance in children than previous concussions, York University study finds
GlobeNewswire
·
April 30, 2025
Toronto, April 30, 2025 (GLOBE NEWSWIRE) -- A new study from York University’s Faculty of Health may offer reassuring news for parents whose children have a history of concussion, but want to get back to playing sports. Researchers from York University’s …
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire
·
April 30, 2025
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that …
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
April 30, 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for …
Altimmune to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …
Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
April 30, 2025
CINCINNATI, April 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Second quarter 2025 financial …
Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid
GlobeNewswire
·
April 30, 2025
NEW YORK and TRUMBULL, Conn., April 30, 2025 (GLOBE NEWSWIRE) -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome, today …
InflaRx to Report First Quarter 2025 Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …